See more : Yuexiu Transport Infrastructure Limited (1052.HK) Income Statement Analysis – Financial Results
Complete financial analysis of RVL Pharmaceuticals plc (RVLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RVL Pharmaceuticals plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Amgen Inc. (AMGN) Income Statement Analysis – Financial Results
- Hipolin Limited (HIPOLIN.BO) Income Statement Analysis – Financial Results
- Raffles Interior Limited (1376.HK) Income Statement Analysis – Financial Results
- Life Insurance Corporation of India (LICI.NS) Income Statement Analysis – Financial Results
- The Erawan Group Public Company Limited (ERW.BK) Income Statement Analysis – Financial Results
RVL Pharmaceuticals plc (RVLP)
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 49.72M | 17.50M | 27.76M | 240.03M | 263.70M | 245.75M | 218.46M |
| Cost of Revenue | 9.46M | 3.62M | 3.29M | 111.63M | 140.08M | 125.19M | 125.62M |
| Gross Profit | 40.27M | 13.88M | 24.47M | 128.40M | 123.62M | 120.56M | 92.84M |
| Gross Profit Ratio | 80.98% | 79.33% | 88.14% | 53.49% | 46.88% | 49.06% | 42.50% |
| Research & Development | 3.97M | 6.93M | 13.39M | 32.32M | 43.69M | 42.69M | 29.06M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 81.98M | 87.46M | 72.82M | 93.03M | 74.24M | 56.95M | 65.96M |
| Other Expenses | 6.26M | -1.33M | -48.00K | 884.00K | 664.39K | -4.52M | 168.73K |
| Operating Expenses | 85.95M | 94.39M | 86.21M | 125.35M | 117.94M | 99.64M | 95.02M |
| Cost & Expenses | 95.40M | 98.01M | 89.50M | 236.98M | 258.02M | 224.83M | 220.64M |
| Interest Income | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.11M | 4.02M | 4.10M | 18.21M | 20.79M | 29.05M | 20.19M |
| Depreciation & Amortization | 9.49M | 6.84M | 20.98M | 57.02M | 81.57M | 46.45M | 23.59M |
| EBITDA | -36.19M | -73.67M | -40.76M | 60.95M | -664.39M | 62.85M | 21.58M |
| EBITDA Ratio | -72.78% | -420.94% | -146.83% | 25.39% | 33.34% | 25.57% | 9.88% |
| Operating Income | -45.68M | -80.51M | -61.74M | 3.94M | -98.54M | -52.07M | -32.05M |
| Operating Income Ratio | -91.87% | -460.03% | -222.40% | 1.64% | -37.37% | -21.19% | -14.67% |
| Total Other Income/Expenses | -6.03M | 315.00K | -33.05M | -301.96M | -20.13M | -33.57M | -20.02M |
| Income Before Tax | -51.71M | -82.53M | -94.80M | -298.02M | -118.66M | -85.64M | -52.07M |
| Income Before Tax Ratio | -104.00% | -471.60% | -341.46% | -124.16% | -45.00% | -34.85% | -23.83% |
| Income Tax Expense | -20.00K | 315.00K | -5.78M | -27.12M | -8.98M | -40.49M | -10.25M |
| Net Income | -51.69M | -82.85M | -89.01M | -270.90M | -109.68M | -45.15M | -41.82M |
| Net Income Ratio | -103.96% | -473.40% | -320.63% | -112.86% | -41.59% | -18.37% | -19.14% |
| EPS | -0.58 | -1.23 | -1.47 | -5.17 | -2.42 | -1.05 | -0.98 |
| EPS Diluted | -0.58 | -1.23 | -1.47 | -5.17 | -2.42 | -0.98 | -0.98 |
| Weighted Avg Shares Out | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 42.86M | 42.85M |
| Weighted Avg Shares Out (Dil) | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 45.86M | 42.85M |
RVL Completes Financial Restructuring
Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities
Why Is RVL Pharmaceuticals (RVLP) Stock Up 40% Today?
RVL Pharmaceuticals (NASDAQ: RVLP ) stock is rising higher on Wednesday even without any news from the specialty pharmaceutical company. Shares of RVL Pharmaceuticals stock are climbing today despite the company not putting out any new press releases.
RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries
Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be...
Why Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?
RVL Pharmaceuticals (NASDAQ: RVLP ) stock is climbing higher on Friday despite a lack of news from the specialty pharmaceutical company. There aren't any new press releases of filings with the Securities and Exchange Commission (SEC) that explain why the shares...
RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings...
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying...
RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review
-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as...
RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update
-- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET -- -- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET --
RVL Pharmaceuticals: A First 'Look'
Today we take our first look at RVL Pharmaceuticals plc, a small ocular-focused concern. RVL Pharmaceuticals plc recently launched the first and only FDA-approved ophthalmic solution to treat low-lying eyelids in adults.
RVL Pharmaceuticals plc (RVLP) Q3 2022 Earnings Call Transcript
RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lisa Wilson – Investor Relations Brian Markison – Chief Executive Officer JD Schaub – Chief Operating Officer Mike DePetris – Interim Chief...
Source: https://incomestatements.info
Category: Stock Reports